Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

AKBA

0.00
  • Akebia Therapeutics posted Q1 2026 revenue of $53.5 million, down 6.63%, swinging to a net loss of $9.1 million.
  • Vafseo net product revenue rose 31.67% to $15.8 million, while Auryxia net product revenue fell 17.35% to $36.2 million.
  • Research and development expense climbed 51.02% to $14.8 million, selling, general and administrative expense increased 18.29% to $30.4 million.
  • Vafseo patient count increased about 60% versus Q4 2025; prescribers rose about 28% to roughly 1,025.
  • Akebia reiterated expectations for VOCAL Phase 3b topline data in Q4 2026, with VOICE Phase IV topline data expected in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070700PRIMZONEFULLFEED9714948) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.